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Arrhythmogenicity and electrophysiological
effects of anti-Ro ⁄SSA antibodies
Based on the facts that there is no convincing evidence
that maternal antibodies can cross the sarcolemma of a
normal cardiac myocyte, essentially two major categories
of mechanisms for congenital complete heart block
(CHB) can be identified. The first is abnormal surface
expression of intracellular SSA ⁄Ro and SSB ⁄La antigens,
eventually induced by apoptosis [1, 2], viral infection [3],
UV light and IFNc treatment [4]. The other mechanism
is the cross-reactivity of maternal antibodies with targets
other than SSA ⁄Ro and SSB ⁄La antigens. Maternal anti-
bodies were reported to cross-react with laminin and with
human cardiac myosin heavy chain at a critical stage dur-
ing foetal cardiac development [5, 6], but the L-type cal-
cium channels seem particularly important in this
hypothesis [7–10].
After preliminary reports, [11, 12] Boutjdir in an out-
standing paper [7] showed that IgG-enriched fractions
and anti-52-kD SSA ⁄Ro antibodies affinity-purified from
the sera of mothers whose children have CHB reversibly
induce complete atrioventricular (AV) block in the
human foetal heart perfused by the Langendorff tech-
nique. At 33 min of perfusion, complete AV block was
observed with the presence of only P waves and missing
QRS complexes. Reperfusion of the heart with antibody-
free Tyrode’s solution for 48 min resulted in partial and
slow recovery. Superfusion of hearts with IgG fractions
from mothers with affected children also induced brady-
cardia and AV dissociation. In contrast, IgG from control
mothers did not have any measurable effect on AV
conduction. In the same paper, the authors showed that
anti-Ro ⁄ SSA antibodies inhibit L-type Ca2+currents at
the whole-cell and single-channel level. Immunization of
female BALB ⁄ c mice with recombinant 52-kD SSA ⁄Ro
protein generated high-titre antibodies that crossed the
placenta during pregnancy and were associated with vary-
ing degrees of AV conduction abnormalities, including
complete AV block, in the pups. These findings suggest
that anti-52-kD SSA ⁄Ro antibodies are causally related
to the development of CHB.
The same group reported that the passive transfer
of human anti-Ro/SSA into pregnant mice induced
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Abstract
Perfusion of human foetal heart with anti-Ro ⁄ SSA antibodies induces transient
heart block. Anti-Ro ⁄ SSA antibodies may cross-react with T- and L-type cal-
cium channels, and anti-p200 antibodies may cause calcium to accumulate in
rat heart cells. These actions may explain a direct electrophysiological effect of
these antibodies. Congenital complete heart block is the more severe manifes-
tation of so-called ‘‘Neonatal Lupus’’. In clinical practice, it is important to
distinguish in utero complete versus incomplete atrioventricular (AV) block, as
complete AV block to date is irreversible, while incomplete AV block has
been shown to be potentially reversible after fluorinated steroid therapy.
Another issue is the definition of congenital AV block, as cardiologists have
considered congenital blocks detected months or years after birth. We propose
as congenital blocks detected in utero or within the neonatal period (0–27 days
after birth). The possible detection of first degree AV block in utero, with dif-
ferent techniques, might be a promising tool to assess the effects of these anti-
bodies. Other arrhythmias have been described in NL or have been linked to
anti-Ro ⁄ SSA antibodies: first degree AV block, in utero and after birth, second
degree (i.e. incomplete block), sinus bradycardia and QT prolongation, both in
infants and in adults, ventricular arrhythmias (in adults). Overall, these
arrhythmias have not a clinical relevance, but are important for research
purposes.
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..................................................................................................................................................................
 2010 The Authors
198 Journal compilation  2010 Blackwell Publishing Ltd. Scandinavian Journal of Immunology 72, 198–204
bradycardia and first degree AV blocks in the pups [8].
However, the penetrance was extremely low, paralleling
human disease frequencies. Similarly, we reported the
occurrence of sinus bradycardia in newborns of anti-
Ro ⁄ SSA-positive women [13]. The rationale is that
impulse generation at the sinoatrial node and conduction
at the AV node critically depends on ICa-L.
In other experiments, the Swedish group [14] showed
that maternal autoantibodies directed to a specific epitope
within the leucine zipper amino acid sequence 200–239
(p200) of the Ro52 protein correlated with prolongation
of foetal AV time and heart block.
QT interval prolongation has been inconsistently
observed both in infants exposed to anti-Ro ⁄ SSA and in
anti-Ro ⁄ SSA-positive adults [15, 16]; a clear physiologi-
cal basis for this possible effect is lacking at present, even
if it has been hypothesized [17].
Clinical features
Complete AV block (Congenital complete heart block; third
degree AV block)
Third degree AV block is the most severe manifestation
of neonatal lupus as it is irreversible and carries a high
morbidity and mortality rate. The presence of signs or
symptoms is mainly related to the ventricular rate, which
usually ranges between 30 and 100 beats ⁄min [18, 19],
but may be also related to the cardiac contractility and
to the ratio of atrial to ventricular contractions; heart rate
usually declines during the pregnancy [20], the lower the
rate, the higher the possibility of foetal hydrops and neo-
natal cardiac failure, and foetal or neonatal death corre-
lates with a ventricular rate in utero £55 bpm [18–21].
Complete heart block (CHB) (either first, second, or
third) is most frequently detected in utero by prenatal
ultrasound, between 18 and 24 weeks of gestational age.
This ‘‘window’’ coincides with the timing of placental
transfer (that becomes effective at about 12 weeks) and
the timing of the development of the human foetal con-
duction system which is formed by 12 weeks (thus
explaining the absence of associated structural abnormali-
ties) but presumably undergoes further remodelling. In
the majority of cases, complete block requires a pace-
maker implantation, frequently but not necessarily in the
neonatal period. In utero death is usually related to intrac-
table heart failure, but may be sudden and unexpected
(personal observation).
Differential diagnosis: complete AV block (third degree) vs
incomplete AV block (second degree). At first appearance of a
foetal bradycardia, it can be difficult and time-consuming
to differentiate between certain types of second degree
(incomplete) AV blocks and third degree (complete) AV
block, but this distinction might be important, as com-
plete AV block to date is irreversible, while incomplete
AV block has been shown to be potentially reversible
after dexamathasone or bethametasone therapy [22, 23].
The distinction is critically dependent on the analysis of
the relationship between atrial and ventricular contrac-
tions during foetal echocardiography. If the block is com-
plete (third degree), atrial and ventricular contractions
are completely dissociated. If the AV block is incom-
plete, second degree, some atrial contractions are not fol-
lowed by ventricular contractions. Problems in particular
may arise if the incomplete AV block has a fixed ratio
2:1 between atrial and ventricular contractions; in fact,
this sequence may be difficult to ascertain echographical-
ly, with the consequence that an incomplete second
degree AV block (potentially reversible) may be errone-
ously considered as complete (irreversible) [23]. Also
blocked atrial premature contractions might be misinter-
preted as second degree block.
Definitions, implications, and the problem of anti-Ro ⁄ SSA-
negative blocks. Immunologists and rheumatologists
understand as congenital a block ‘‘existing at or dating
from birth’’. In contrast, cardiologists often use Yater’s
criteria: ‘‘heart block established in a young patient.
There must be some evidence of the existence of the slow
pulse at a fairly early age and absence of a history of any
infection which might cause the condition after birth:
notably diphtheria, rheumatic fever, chorea and congeni-
tal syphilis’’ [24]. Thus, it is evident that when immu-
nologists, cardiologists, and obstetricians write about
CHB, they may not be describing the same clinical or
pathological entity [25].
To reduce the existing confusion in the literature, we
recommended a change from the existing definition
(Yater 1929).We proposed a new definition of isolated
congenital complete AV block, acceptable to cardiolo-
gists, rheumatologists, immunologists, obstetricians, pae-
diatricians: ‘‘an AV block is defined as congenital if it is
diagnosed in utero, at birth, or within the neonatal period (0–
27 days after birth)’’ [25, 26]. Accumulated data reveal
that the large majority of cases detected in utero and not
associated with structural heart defects causally linked
with CHB are associated with the presence of anti-
Ro ⁄ SSA antibodies in the mothers, while heart blocks
detected after birth are generally not associated with
maternal autoantibodies [25, 27]. The percentages of
anti-Ro ⁄ SSA positivity vary according to the laboratory
method employed (counterimmunoelectrophoresis, immu-
noblot, ELISA-commercial kits, ELISA-home made) as
different methods have different sensitivities and different
specificities. Immunological studies using the most sensi-
tive and advanced methods approach 100% of positivity
[25, 28]. In these studies, there may have been a selection
bias; in fact mothers may have been selected based on a
diagnosed or suspected connective tissue disease, as these
cases were collected mainly from rheumatological centres.
On the other hand, cardiological studies generally report
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lower percentages of anti-Ro ⁄ SSA-positive cases (e.g.
65%), but details of methods employed to detect the
antibodies often are lacking [18, 21, 27, 28].
Anyway advanced (second or third degree) AV blocks
detected in utero or at birth and definitely anti-Ro ⁄ SSA
negative exist; in an unselected series of 45 consecutive
cases, we observed that 20% were anti-Ro ⁄ SSA negative,
a finding that surprised us but was confirmed in several
laboratories, including Ed Chan lab. These anti-Ro ⁄ SSA-
negative blocks were less stable and complete than the
anti-Ro ⁄La-positive ones [28].
Assessment of first degree AV Block in utero
Several methods have been developed with the aim to
detect in utero early foetal abnormalities, particularly 1st
degree AV block that might herald CHB. The American
group have evaluated the mechanical PR interval [29].
By using the gated-pulsed Doppler technique, time inter-
vals from the onset of the mitral A wave (atrial systole)
to the onset of the aortic pulsed Doppler tracing (ventric-
ular systole) within the same left ventricular cardiac cycle
may be measured. Ninety-five pregnant women with
anti-Ro ⁄ SSA antibodies completed an evaluable course in
98 pregnancies. The protocol included foetal echocardio-
grams performed weekly from 16 to 26 weeks’ gestation.
PR intervals >150 ms were considered prolonged, consis-
tent with 1st degree block. Ninety-two foetuses had nor-
mal PR intervals. Neonatal lupus developed in 10 cases;
four were neonatal lupus rash only. Three foetuses had
3rd degree block; none had a preceding abnormal PR
interval, although in two foetuses >1 week elapsed
between echocardiographic evaluations. Tricuspid regur-
gitation preceded 3rd degree block in one foetus, and an
atrial echodensity preceded block in a second. Two foe-
tuses had PR intervals >150 ms. Both were detected at
or before 22 weeks, and each reversed within 1 week
with 4 mg dexamethasone. No 1st degree block devel-
oped after a normal ECG at birth. Heart block occurred
in three of 16 pregnancies (19%) in mothers with a pre-
vious child with CHB and in three of 74 pregnancies
(4%) in mothers without a previous child with CHB or
rash (P = 0.067). The authors concluded that prolonga-
tion of the PR interval was uncommon and did not pre-
cede more advanced block and that advanced block and
cardiomyopathy can occur within 1 week of a normal
echocardiogram without initial 1st degree block. Echo-
densities and moderate ⁄ severe tricuspid regurgitation
merit attention as early signs of injury [29].
The Swedish group reported on weekly echocardio-
grams performed on 24 women with anti-Ro ⁄ SSA 52-kd
antibodies, between 18 and 24 weeks of gestation, with
two Doppler echocardiographic methods designed to esti-
mate the time delay between hemodynamic events caused
by atrial and ventricular depolarizations [30]. Foetal AV
time intervals were longer, and heart rates were slightly
lower compared to foetuses not exposed to anti-Ro ⁄ SSA
antibodies. Eight foetuses had signs of 1st degree block.
It is of note that the cut-offs for 1st degree block were
lower than those reported by Friedman [29]. One of these
foetuses (whose PR interval was abnormal in the Swedish
study but would not have been considered abnormal in
the US study) had progression to complete block, and
another showed recovery from 2nd degree block to 1st
degree block, with betamethasone treatment. In the
remaining six foetuses, spontaneous normalization
occurred before or shortly after birth [30].
An Israelian group proposed the tissue velocity–based
foetal kinetocardiogram (FKCG) to detect first degree
atrioventricular block in foetuses at risk [31]. FKCG was
performed in 70 foetuses of 56 anti-Ro ⁄ SSA-positive
mothers. Foetuses were monitored with weekly FKCG
from 13 to 24 weeks’ gestation and compared to 109 nor-
mal foetuses. FKCG was obtained readily in all foetuses;
six showed 1st degree block (AV conduction time >2 z
scores above normal mean) at 21 to 34 gestational weeks.
Immediate maternal treatment with dexamethasone
resulted in normalization of AV conduction in all affected
foetuses within 3 to 14 days. The ECG PR interval imme-
diately after birth was normal in all affected newborns. No
child developed complete CHB or cardiomyopathy in the
subsequent 1- to 6-year (median 4-year) follow-up.
What is unknown from these three studies is the nat-
ural history of so-called 1st degree block. There are no
data on spontaneous reversibility, and progression to
advanced block has not been reproducibly documented
to date. This is critical and investigators are encouraged
to share echocardiographic tapes to validate the reliability
of this candidate biomarker [32].
Spectrum and progression of conduction abnormalities in
infants born to mothers with anti-Ro ⁄ La antibodies
To ascertain the spectrum of arrhythmias associated with
maternal anti-Ro ⁄La antibodies, records of all children
enrolled in the Research Registry for Neonatal Lupus
were reviewed [33]. Of 187 children with CHB whose
mothers have anti-Ro ⁄La antibodies, nine had a pro-
longed PR interval on ECG at birth, four of whom pro-
gressed to more advanced AV block. A child whose
younger sibling had 3 block was diagnosed with 1
block at age 10 year at the time of surgery for a broken
wrist. Two children diagnosed in utero with 2 block were
treated with dexamethasone and reverted to normal sinus
rhythm by birth, but ultimately progressed to 3 block.
Four children had 2 block at birth: of these, two pro-
gressed to 3 block. These data have important research
and clinical implications.
Perhaps many foetuses sustain mild inflammation, but
resolution is variable, as suggested by the presence of
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incomplete AV block in some cases and progression to
complete block in others. Importantly, as subsequent
progression of less-advanced degrees of block can occur,
an ECG (to identify clinically silent first degree block)
should be performed on all infants born to mothers with
anti-Ro ⁄La antibodies.
QT interval prolongation
QTc prolongation reflects cardiac repolarization prolonga-
tion and increased repolarization inhomogeneity associ-
ated with an increased risk of arrhythmias; it is also seen
in the presence of cardiac failure (e.g. ischaemic heart dis-
ease). On the other hand, in clinical practice, a mild peri-
natal QT prolongation has a questionable clinical
significance as it usually normalizes within few months
after birth.
Years ago, we observed an infant - born to an anti-
Ro ⁄ SSA-positive mother - who presented a marked QT
prolongation in the absence of AV conduction abnormal-
ities. As it has been shown in a study of more than
33,000 infants that the risk of sudden infant death is
41 times greater when QTc>440 msec [34], we have
then analysed the ECG tracings for QT interval mea-
surement of other anti-Ro ⁄ SSA-positive infants who did
not have CHB, as well as those of a control group of
anti-Ro ⁄ SSA-negative infants born to mothers with
autoimmune diseases but negative for these autoantibod-
ies. The study was performed in 21 anti-Ro ⁄ SSA-posi-
tive and seven anti-Ro ⁄ SSA-negative infants. A standard
12-lead ECG, recorded during the first 6 months of life
(mostly at the third month), was analysed for each sub-
ject. QT and RR intervals were measured in lead two
from five non-consecutive beats by a single investigator
who was blinded to the infant’s antibody status. Cor-
rected QT (QTc) was automatically calculated according
to the Bazett’s formula. Positive and negative infants
did not differ significantly for PR interval and QRS
duration, whereas QTc interval was significantly greater
in the group with anti-Ro ⁄ SSA antibodies (442 ± 35
versus 403 ± 16 msec, P = 0.001). When we analysed
the individual values of QTc, we observed that 9 ⁄21
(43%) of the infants with anti-Ro ⁄ SSA had a QTc
>440 msec, the upper normal limit (97.5th percentile)
established in the previously mentioned large prospective
study of more than 33,000 infants [34]. By contrast, all
infants without anti-Ro ⁄ SSA antibodies had a QTc
within the normal limits [15]. We then followed the
children with prolonged QTc to evaluate the relation-
ship between electrocardiographic abnormalities and the
disappearance of autoantibodies from the babies’ circula-
tion. Interestingly, we observed a concomitant disappear-
ance of electrocardiographic abnormalities and of
acquired maternal autoantibodies during the first year of
life [35].
In agreement with these findings, Gordon have
described that the QTc is longer in children of anti-
Ro ⁄ SSA-positive mothers, and even longer in those with
siblings with CHB [36].
These data on QT prolongation were then largely dis-
proved by more recent and larger studies that did not
show any QT prolongation in infants from anti-Ro ⁄ SSA-
positive women.
The French group studied 165 consecutive pregnan-
cies in 106 anti-SSA-positive women with connective
tissue diseases (CTDs) [37]. ECGs obtained on 58 chil-
dren of this group were compared with those obtained
on 85 infants born to mothers with CTDs who were
negative for both anti-SSA and anti-SSB. For ECGs
recorded during the first 2 months of life, the
mean ± SD PR interval was 96 ± 16 msec in the anti-
SSA-positive group and 96 ± 13 msec in the anti-SSA-
negative group (P = 0.84), with mean QTc values of
397 ± 27 and 395 ± 25 msec (P = 0.57) and mean
heart rates of 141 ± 23 and 137 ± 21 beats per min
(P = 0.20), respectively. No difference in the PR inter-
val, QTc interval, or heart rate was observed for ECGs
obtained between 2 and 4 months of life. When ECGs
obtained at 0–2 months were compared with those
obtained at 2–4 months, a physiological prolongation of
the QTc interval was observed in both study groups. No
sudden infant death or symptomatic arrhythmia occurred
during the first year of life. The authors concluded that
the ECG findings in children of anti-SSA-positive and
anti-SSA-negative mothers were not significantly differ-
ent [37]. However, this study was mainly retrospective.
Thus, larger and prospective studies are needed to assess
the real prevalence of these ECG abnormalities in the
population of infants born to mothers with autoimmune
diseases.
Also, the American group did not find any prolonga-
tion of QT interval in a prospective study of 98 infants,
but in this study, a control group was lacking [29].
Thus, overall, QT prolongation as a consequence of auto-
antibody injury remains unproven.
An intriguing finding has been raised by Lazzerini,
who showed in a ECG-resting study that anti-Ro ⁄ SSA-
positive patients frequently (58% of the cases) show a
QTc interval prolongation (with mean values above the
upper normality limit of 440 msec) [16]. Thus, he
hypothesized that anti-Ro ⁄ SSA antibodies may exert a
direct arrhythmogenic effect, thereby providing patients
bearing such antibodies with a high risk of developing
arrhythmias, as QTc interval prolongation is a definite
risk factor for arrhythmic sudden death in the general
population. Conversely, a later study of Costedoat-Chalu-
meau [38] evaluating 32 anti-Ro ⁄ SSA positive in com-
parison with 57 anti-Ro ⁄ SSA-negative CTD patients
(almost exclusively patients with SLE) found no differ-
ences in QTc interval duration.
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In another study by Gordon, in which the SLE pre-
ponderance was less extreme, the QTc interval was
reported to be longer in the anti-Ro ⁄ SSA positive than
in the anti-Ro ⁄ SSA-negative group, and this difference,
although not significant, indeed approached significance
(P = 0.063) [39].
Starting from this background, a 24-hour electrocar-
diographic monitoring study was performed by Lazzerini
to investigate the possible relation between QTc interval
prolongation and incidence of ventricular arrhythmias as
a possible expression of immuno-mediated electric insta-
bility of the myocardium in anti-Ro ⁄ SSA-positive adult
patients [40] The study population consisted of 46
patients with connective tissue disease; 26 anti-Ro ⁄ SSA-
positive and 20 anti-Ro ⁄ SSA-negative (control group)
patients. With respect to the control group, anti-
Ro ⁄ SSA-positive patients commonly showed QTc interval
prolongation (46% versus 5%), and this abnormality,
when present, persisted for the 24 h (global mean 24-h
QTc interval 440.5 ±23.4 versus 418.2 ±13.2 ms); they
also had a higher incidence of complex ventricular
arrhythmias (i.e., Lown classes 2–5, 50% versus 10%)
also in the absence of detectable cardiac abnormalities. In
these patients, there was a direct relation between global
mean 24-hour QTc interval and ventricular arrhythmic
load independently of age and disease duration. These
authors concluded that anti-Ro ⁄ SSA-positive patients
seemed to have a higher risk of developing ventricular
arrhythmias. The risk appeared related mainly to abnor-
malities in ventricular electrophysiological characteristics
emerging in the clinical setting as QTc interval prolon-
gation [40, 41].
Sinus bradycardia
We described in a previous paragraph how anti-Ro ⁄ SSA
antibodies may cross-react with the calcium channels so
interfering with the functioning of sinoatrial node, and
Mazel reported that passive transfer of human anti-
Ro ⁄ SSA and anti-La ⁄ SSB autoantibodies into naive preg-
nant mice induced bradycardia [9]. We observed similar
findings in humans [13, 42]. In four infants, a significant
transient sinus bradycardia was observed (heart rate <3
centile for age). Prenatal ultrasound foetal heart rate was
normal; no perinatal complication (in particular, no met-
abolic or thermal problems) was observed, and possible
causes of bradycardia in newborns were excluded, e.g.
electrolytes’ abnormalities and drug interferences. In all
cases, bradycardia disappeared within 10 days after birth,
with no sequelae. Two mothers had systemic lupus eryth-
ematosus and two had an undifferentiated connective tis-
sue disease. Our observations indicate that sinus
bradycardia and sinus node dysfunction do not occur only
in experimental animals passively transfused with anti-
Ro ⁄ SSA antibodies but that they might be detectable
also in rare cases in human newborns. In the Research
Registry for Neonatal Lupus, data on atrial rates were
sought among the 187 records reviewed. Atrial rates of
78 foetuses were recorded in utero by echocardiogram; the
mean rate was 138 bpm ± 17 SD, range 68–160. Three
foetuses (3.8%) had atrial rates less than 100 bpm. The
rate of one increased from 68 to 158 on postnatal ECG.
The rate of the second increased minimally from 95 to
104 on postnatal ECG. The third had a rate of 95 bpm
in utero and a postnatal ECG was not provided. Atrial
rates from postnatal ECGs were available for 40 neonates;
the mean rate was 137 bpm ± 20 SD, range 75–200.
The one slow rate of 75 bpm was obtained during sleep
and increased to 140 bpm when awake. In an additional
child, the records stated sinus bradycardia; however, no
ECG was available and subsequent records were not sent
to the Registry [33].
The French group did not observe any case of sinus
bradycardia in their cohort of 58 children [37].
Sinus bradycardia, first degree AV block, QT prolongation:
where we are now?
As described previously, the field is confused, with con-
tradictory findings. Some of these discrepancies are
explained by the time of recording of ECG. In fact, nor-
mal values of infants ECG are strongly dependent on the
age of the infants. In particular, 1- year follow-up clearly
demonstrated that QT interval prolongation was transient
and disappeared within the sixth month of life in almost
all cases [43]. The best studies that we have for the
moment are probably the two following ones. In fact,
two useful prospective studies have been recently pub-
lished by Italian groups. In the first study [44], electro-
cardiograms prospectively obtained from 51 infants born
of anti-Ro ⁄ SSA-positive mothers were compared with
those obtained from 50 control infants born of mothers
with anti-extractable nuclear antigen (ENA)–negative
connective tissue disease. One anti-Ro ⁄ SSA exposed
infant developed complete CHB. No infant showed sinus
bradycardia. First degree AV block at birth was observed
in five study group and no control group infants,
P = 0.023. First degree AV blocks spontaneously
reverted during the first year of life. Mean corrected QT
value of infants born to anti-Ro ⁄ SSA-positive mothers
was slightly prolonged but did not reach statistical sig-
nificance, when compared with the control group
(0.404 s versus 0.395 s; P = 0.060).
In the second study [43], 60 anti-Ro ⁄ SSA-positive and
36 anti-Ro ⁄ SSA-negative autoimmune mothers were
prospectively followed; ECG and ⁄ or ECG-Holter were
performed on the offspring at 1st, 3rd, 6th, and
12th month. One of sixty-one foetuses of anti-Ro ⁄ SSA-
positive mothers developed third degree block, one devel-
oped 2nd degree AV block (30th week). Corrected QT
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interval ‡440 msec was observed in 13% of cases and in
20% of controls at the first ECG. ECG-Holter showed
QTc prolongation ‡440 msec in 59% infants of anti-
Ro ⁄ SSA-positive mothers and in 60% of controls, and
QTc ‡470 msec in four infants of anti-Ro ⁄ SSA-positive
group and in two controls. One baby in the anti-
Ro ⁄ SSA-positive and two in the anti-Ro ⁄ SSA-negative
group required beta-blockers. Genetic causes of QTc pro-
longation were excluded. This prospective study showed
that ECG abnormalities (1st degree block and QTc
prolongation) are frequent in infants of mothers with
autoimmune diseases particularly if ECG-Holter is per-
formed, independently of maternal autoantibody profile.
One-year follow-up clearly demonstrated that QT interval
prolongation was transient and disappeared within the
sixth month of life in almost all cases. [43]. Finally, as
some studies have reported cardiotoxicity and conduction
or repolarization abnormalities in patients treated with
anti-malarial agents, drugs which have been shown to
cross the placenta, these authors also assessed the presence
of possible correlations between QT interval prolongation
and maternal therapy with hydroxychloroquine during
pregnancy. The prevalence of QT interval prolongation
was not significantly different in the neonates born to
mothers treated with anti-malarials during pregnancy
and in those born to mothers who did not receive them
[43].
Key points
Many electrocardiographic abnormalities may probably be
rarely present in infants born to anti-Ro ⁄ SSA-positive
women (and perhaps also in anti-Ro ⁄ SSA-positive adults),
but these abnormalities are mild and not clinically rele-
vant, even if their study may be very important for
research as are probably related to some cross-reactions of
anti-Ro ⁄ SSA antibodies with ion channels.
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